

827 **Adaptor bypass mutations of *Bacillus subtilis* *spxA* suggest a mechanism**
828 **for YjbH-enhanced proteolysis of the regulator Spx by ClpXP**

829

830

831

832

Chio Mui Chan Erik Hahn and Peter Zuber

833

834

835

836

837

Supplemental material

838

839
840
841
842
843 Supplementary Tables

844

845 **TableS1.** *Bacillus subtilis* strains and plasmids used in this study

Strains or plasmids	Relevant genotype or properties	Reference
Strains		
ORB7852	<i>trpC2 pheA1 spx::neo yjbH::tet^F</i>	(Kommineni <i>et al.</i> , 2011)
ORB8729	<i>trpC2 pheA1 spx::neo yjbH::tet^F amyE:: P_{hyspank}-spx(wt)</i>	
ORB8731	<i>trpC2 pheA1 spx::neo yjbH::tet^F amyE:: P_{hyspank}-spx(F113A)</i>	
ORB8732	<i>trpC2 pheA1 spx::neo yjbH::tet^F amyE:: P_{hyspank}-spx(L114A)</i>	
ORB8750	<i>trpC2 pheA1 rpoA(cxs-1, Y263C) spx::neo yjbH::tet^F amyE:: P_{hyspank}-spx(WT)</i>	
ORB8752	<i>trpC2 pheA1 rpoA(cxs-1, Y263C) spx::neo yjbH::tet^F amyE:: P_{hyspank}-spx(F113A)</i>	
ORB8753	<i>trpC2 pheA1 rpoA(cxs-1, Y263C) spx::neo yjbH::tet^F amyE:: P_{hyspank}-spx(L114A)</i>	
ORB8968	<i>trpC2 pheA1 spx::neo yjbH::tet^F amyE:: P_{hyspank}-spx(F113A), clpX::erm</i>	
Plasmids		
pET23a	Protein expression vector with C-terminal His ₆ tag	
pPROEX-1	Protein expression vector with cleavable N-terminal His ₆ tag by γ TEV (tobacco etch virus) protease	
pDG646	Source of erythromycin resistance cassette	
pDR111	<i>amyE</i> integration vector with <i>P_{hyspank}</i> promoter	
pSN17	pPROEX-1 derivative encoding N-terminal His ₆ -tagged Spx.	
pEC-27	pPROEX-1 with AbrB with SFQLREAQRLAN at its C-terminus (Spx C-terminus last 12 a.a.)	
pEC-31	pPROEX-1 with AbrB with GYNEDEIRRFLPRKVRSFQLREAQRLAN at its C-terminus (Spx C-terminus last 28 a.a.)	
pEC-33	pPROEX-1 with <i>spx(R112A)</i>	
pEC-35	pPROEX-1 with <i>spx(R111A/R112A)</i>	
pEC-53	pDR111 with <i>spx(wt)</i>	
pEC-56	pPROEX-1 with <i>spx(F113A)</i>	
pEC-57	pPROEX-1 with <i>spx(I110A)</i>	
pEC-58	pPROEX-1 with <i>spx(L114A)</i>	
pEC-59	pPROEX-1 with <i>spx(P115A)</i>	
pEC-61	pDR111 with <i>spx(F113A)</i>	
pEC-62	pDR111 with <i>spx(L114A)</i>	
pEC-66	pDG646 with <i>clpX (166-800)</i>	
pAL-108	pDR111 with <i>spx(R112A^{DD})</i>	
pAL-109	pDR111 with <i>spx(R111A/R112A^{DD})</i>	

846 **Table S2.** Primers

Primer	Sequence
--------	----------

EC35	TAGGCCATATGTTTATGAAATCTACTGGTATTGTAC
EC36	TAGGCGCGGCCGCTCAGTTTGCCAAACGCTGTGCTTCTCTTAATTGGAAAGAT TTAAGGTTTTGAAGCTGGTTTT
EC40	TAGGCGCGGCCGCTTAGTTTGCCAAACGCTGTGCTTCTCTTAATTGGAAAGAG CGAACTTTTCTTTAAGGTTTTGAAGCTGGTTTT
EC41	TAGGCGCGGCCGCTTAGTTTGCCAAACGCTGTGCTT
EC42	AAAACCAGCTTCAAACCTTAAAGGATATAACGAAGACGAAATCA
EC43	TGATTTTCGTCTTCGTTATATCCTTTAAGGTTTTGAAGCTGGTTTT
EC64	TAGGCGCTAGCTTAGTTTGCCAAACGCTGTGCTT
EC78	TAGGGAAGCTTAGAGAACAAGGAGGAGTAGTCACATGGTTACACTATACACAT CAC
EC79	AACGAAGACGAAGCCAGACGTTTCCTG
EC80	CAGGAAACGTCTGGCTTCGTCTTCGTT
EC81	CGAAATCAGACGTGCCCTGCCAAGAAAA
EC82	TTTTCTTGGCAGGGCACGTCTGATTTTCG
EC83	AATCAGACGTTTCGCGCCAAGAAAAGTTC
EC84	GAACTTTTCTTGGCGCGAAACGTCTGATT
EC85	AGACGTTTCCTGGCAAGAAAAGTTCGC
EC86	GCGAACTTTTCTTGCCAGGAAACGTCT
EC90	TAGGCTCTAGAGTAGAATTTAAAGACGTACCAAAG
EC91	TAGGCTCTAGACCGAATCCAATCACTTTTTGCG
o-sn01-6	GGGAATTCCATATGGTTACACTATACACATC
o-sn01-7	CGCGGATCCTTAGTTTGCCAAACGCTGTG

847
848

849

850 Supplementary figure legends

851

852 **Fig. S1.** Sequence alignment of Spx from *B. subtilis* and *Geobacillus*

853 *thermodenitrificans*. The conserved residues are boxed, with completely

854 conserved residues in magenta, identical residues in yellow, similar residues in

855 cyan, and different residues in white.

856

857 **Fig. S2.** . *In vitro* Ni affinity pull-down experiments to detect interaction between

858 GfYjbH-His₆ and AbrB16 or AbrB28. Binding reactions contained 2.5 μM of each

859 protein, and were incubated at room temperature for 10 min. M, marker; I, input;

860 W, wash; E, elution (Experimental Procedures for details). C, contaminating

861 protein in AbrB16 preparation.

862

863 **Fig. S3.** *In vitro* proteolysis assay of AbrB12, AbrB16, and AbrB28 in the

864 absence of GfYjbH-His₆. AbrB12, AbrB16, or AbrB28 (8 μM), ClpX (3 μM), and

865 ClpP (8 μM) with an ATP-generating system (creatine kinase) were incubated at

866 37 °C for the times (min) indicated (left). Plots of AbrB12, AbrB16, and AbrB28

867 band intensities against time of reaction in separate experiments are shown. The

868 intensities of ClpP protein in each lane were used as internal controls (Zhang &

869 Zuber, 2007). The Spx/ClpP ratio in 0-min time point is defined as 100%. Below

870 the graphs are SDS-polyacrylamide gel images after Coomassie blue staining

871 showing bands of AbrB chimeric protein from samples of ClpXP proteolysis
872 reactions.

873

874 **Fig. S4.** Purification of SpxF113A.

875 **A.** SDS- PAGE shows analyses of SpxF113A samples. UI: uninduced cells; I:
876 induced cells with IPTG; S, P, supernatant and pellet (after French press and
877 centrifugation), respectively.

878 **B.** SDS- PAGE shows SpxF113A Ni-NTA column eluants through denaturation-
879 renaturation procedure.

880

881 **Fig. S5.** *In vitro* transcription of linear *trxB* (60 nt) with additions of Spx variants.

882 1, no Spx; 2, SpxWT; 3, His-SpxWT; 4, His-SpxR112A; 5, His-SpxR111A/R112A;
883 6, His-SpxI110A; 7, His-SpxF113A; 8, His-SpxL114A; 9, His-SpxP115A.

884

885 **Fig. S6.** Interaction of His₆-Spx with GtYjbH before and after
886 denaturation/renaturation. Wild Spx with an N-terminal His₆ tag was subjected to
887 denaturation and on-column renaturation according to the procedure described in
888 materials and methods, except that soluble His₆-Spx was diluted in 10 vols. of
889 denaturation solution (Experimental procedures) before application to the Ni-NTA
890 column. Renaturation and interaction assays were conducted as described in
891 Experimental procedures. A. Interaction of His₆-Spx or denatured and renatured
892 His₆-Spx with GtYjbH. B. GtYjbH only applied to Ni-NTA column, confirming no

893 interaction of GtYjbH with Ni-NTA column. I: input; FT: flow-through; W: wash
894 fraction; E: elution.

895

896 **Fig. S7.**

897 **A** . A plot of Spx (WT, F113A, and L114A) band intensities against time of
898 chloramphenicol treatment is shown in the graph (From Fig. 5A). The intensities
899 of a protein recognized by anti-Spx antiserum in each lane were used as internal
900 controls. The Spx intensity normalized by 0-min time point is defined as 100%.

901

902 **B**. A plot of Spx (F113A) band intensities against time of chloramphenicol
903 treatment is shown in the graph (From Fig. 5B). The Spx intensity normalized by
904 0-min time point as described Fig.5 is defined as 100%.

905

906 **Fig. S8.** Immunoblot analysis of ClpX level using anti-ClpX antiserum in cells
907 bearing the $P_{hyspank^-}$ *spx* (*wt*, *F113A*, or *P114A*) in *yjbH* and *spx* null mutant and
908 in either *rpoA*⁺ (RNAP_{wt}) or *rpoA*Y263C (RNAP_m) genetic backgrounds. Cells
909 were grown to mid-exponential phase, induced with 1 mM IPTG for 1 hr, and
910 followed by 0.1 μg/μl chloramphenicol treatment as indicated in the figure.

911

912

913

Fig. S1

Sequence alignment of *Bacillus subtilis* and *Geobacillus thermodenitrificans* Spx

```
B.subt_Spx  MVTLYTSPSCTSCRKARAWLEEH EIPFVERNIFSEPLSIDEIKQILRMTE DGTDEIISTR
G.ther_Spx  MVKLYTSPSCTSCRKAKAWLEKHDIPYVERNIFSEPLTVEEIKEILRMTE TGTDEIISTR
consensus  MV-LYTSPSCTSCRKArAWLE-HeIPfVERNIFSEPLsideIK-ILRMTE-GTDEIISTR

B.subt_Spx  SKVFQKLNvNvESmPLQDLYRLINEHPGLRRPIIIDEKRLQVGYNEDIIRRFLPRKVRS
G.ther_Spx  SKVFQKLNINLES LPLQDLYELIQKNPGILRRPIIIDEKRLQVGYNEDIIRRFLPRKVRA
consensus  SKVFQKLNvNvESmPLQDLY-LIn--PGlRRPIIIDEKRLQVGYNEDIIRRFLPRKVR-

B.subt_Spx  FQLREAQRLAN-
G.ther_Spx  YQLREAQRLVNG
consensus  fQLREAQRL-Ng
```

Fig. S2




Fig. S3








Fig. S4




Fig. S5




Fig. S6





Fig. S7




Fig. S8

